Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

Researchers have made a significant breakthrough in cancer drug discovery by identifying a new binding site on the eukaryotic initiation factor 4 ...

Mark Erlander; Chief Executive Officer, Director; Cardiff Oncology Inc. James Levine; Chief Financial Officer; Cardi ...

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

Q4 2024 Earnings Call Transcript February 27, 2025 Cardiff Oncology, Inc. beats earnings expectations. Reported EPS is $-0.22 ...

BioArctic AB's (publ) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion for the ...

Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...